Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Other solid neoplasm 1Myeloid 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 70Nivolumab 47Ipilimumab 27Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11Cyclophosphamide 11binimetinib 10Radiotherapy 9CTLA-4 Antigen 9fludarabine 8encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7fludarabine phosphate 6durvalumab 6tislelizumab 5relatlimab 5lenvatinib 5dostarlimab 5Pemetrexed 5Paclitaxel 5Introns 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × cedazuridine × Dermatologic × Clear all
NCT05089370 2025-12-08

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

University of Colorado, Denver

Phase 1/2 Active not recruiting
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡